Skip to content

Efficacy and Tolerance of Sodium Thiosulfate Injection After Ultrasound-guided Percutaneous Irrigation of Calcific Tendinopathy of the Rotator Cuff

Efficacy and Tolerance of Sodium Thiosulfate Injection After Ultrasound-guided Percutaneous Irrigation of Calcific Tendinopathy of the Rotator Cuff

Status
Completed
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02538939
Acronym
THIOCAL
Enrollment
17
Registered
2015-09-02
Start date
2015-12-02
Completion date
2017-11-13
Last updated
2026-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Calcific Tendinitis of the Rotator Cuff

Keywords

Calcific tendinitis, Shoulder, Needle lavage, Sodium thiosulfate

Brief summary

Calcific tendinitis of the rotator cuff is a common cause of chronic pain of the shoulder. US- guided needling and lavage of the calcification is one of the therapeutic options after failure of conservative management with physiotherapy and anti-inflammatory drugs. The goal of this procedure is to remove the calcific deposit that is believed to cause the sub-acromial impingement. However, studies have shown that complete and rapid disappearance of the calcification deposit after irrigation is rare. The treatment is thought to promote the spontaneous resorption that occurs the weeks and months after the procedure. However, due to this slow process, time to complete recovery can be long. Moreover, it has been shown an association between the amount of removed calcium and improved outcome. Therefore, there is a need to find a way to remove quickly and completely the calcific deposit after irrigation. Sodium thiosulfate has been used successfully in the treatment of calciphylaxis and subcutaneous calcification deposit. The mechanism of action involves chelation of calcium into calcium thiosulfate salts which are much more soluble than other salts of calcium. Our hypothesis is that injection of sodium thiosulfate after irrigation of the calcification will help to dissolve the calcific deposit and thus prompt the disappearance of the calcification.

Interventions

DRUGSodium thiosulfate

Sponsors

Nantes University Hospital
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

Critères d'inclusion : * Patients de plus de 18 ans * Patients affiliés à un régime de sécurité sociale * Consentement éclairé et signé des patients * Douleur de l'épaule depuis plus de 3 mois * Douleur compatible avec une origine péri-articulaire : * aggravation lors de l'élévation de l'épaule * 1 des 3 tests de conflit sous-acromial positif (Yocum, Hawkins, Neer) * Présence d'une calcification dure \> 5 mm sur la radiographie standard (calcification de type A de la société Française d'Arthroscopie) (Mole, 1993) * Contraception efficace obligatoire pour les femmes en âge de procréer à maintenir jusqu'au lendemain de l'administration du thiosulfate de sodium. Critères de non-inclusion : * Allergie connue à l'anesthésique, au cortivazol ou au thiosulfate de sodium * Hypersensibilité connue au métabisulfite de sodium (agent de conservation et anti-oxydant connu sous le code E224) * Patients asthmatiques * Insuffisance rénale (Clairance \< 30 mL/min) * Patients sous anticoagulants, troubles de la coagulation * Tableau de résorption aiguë de la calcification (épaule aiguë hyperalgique) * Aspect flou de la calcification sur les radiographies standards évoquant une résorption (calcification de type C de la société Française d'Arthroscopie) (Mole, 1993) ou calcifications fragmentées à contours nets (type B) * Rupture de la coiffe des rotateurs mise en évidence sur l'échographie initiale * Antécédent de PFL sur la calcification étudiée dans les 3 mois précédent l'inclusion * Autre pathologie d'épaule associée (arthrose gléno-humérale, acromio-claviculaire), * Diabète déséquilibré * Contre-indication à la prise d'anti-inflammatoires non stéroïdiens et de paracétamol * Infection locale ou générale, ou suspicion d'infection * Contre-indication à la Xylocaïne 1% : (porphyrie récurrente, β-bloquant dans l'insuffisance cardiaque) * Femmes enceintes, mineurs, majeurs sous tutelle * Femmes en âge de procréer refusant de maintenir une contraception efficace jusqu'au lendemain de la PFL * Patients participant à un autre protocole de recherche clinique (à l'exception de recherches non-interventionnelles) * Patients incapables de suivre le protocole, selon le jugement de l'investigateur

Design outcomes

Primary

MeasureTime frameDescription
Decrease the size of the calcific deposit after the PFL1 monthPercentage of patient having more than 50% decrease in the size of the calcific deposit 1 month after the PFL

Secondary

MeasureTime frame
VAS pain during daily activity (0-10)7 days, 1 month and 3 months
VAS pain at rest (0-10)7 days, 1 month and 3 months
The Disabilities of the Arm, Shoulder and Hand (DASH) Score1 month and 3 months
Size of the calcific deposit assessed by X-Ray of the affected shoulder7 days, 1 month and 3 months
Size of the calcific deposit assessed by ultrasound of the affected shoulder7 days, 1 month and 3 months
Self-reported quality of life assessed by the EQ-5D questionnaire1 month and 3 months
Number of day off work due to the shoulder painup to 3 months

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Sep 15, 2026